Designing Life from Scratch: A Fledgling Field is About to Take Off
By Lisa M. Krieger,
San Jose Mercury News
| 08. 08. 2015
Untitled Document
Mother Nature has always been life's master architect, working off genetic blueprints that are fine-tuned from one generation to the next.
Until now.
Scientists increasingly are designing life from scratch, using inexpensive, fast and accurate tools to create and assemble strands of DNA like tinkertoys -- and instructing cells to do things that nature never imagined.
In industrial clusters in the Bay Area, La Jolla and Boston, the competitive gene-building field is doing for biology what Johannes Gutenberg did for printing -- turning what was once a laborious and uneven artisan effort into affordable and accurate mass production. With the potential to create an industry that could lead to products worth hundreds of billions of dollars, the fast-moving field is not only prompting investor funding but also sparking calls for oversight.
The goal is to build improved medicines, better biofuels and new chemicals -- and perhaps someday splice new genes into sick people, fixing inherited diseases. But the cutting-edge technique also could be used to build dangerous pathogens for warfare.
"We're accelerating genetics," said biochemist Emily Leproust, cofounder...
Related Articles
By Abby McCloskey, The Dallas Morning News | 10.10.2025
We Texans like to do things our way — leave some hide on the fence rather than stay corralled, as goes a line in Wallace O. Chariton’s Texas dictionary This Dog’ll Hunt. Lately, I’ve been wondering what this ethos...
By Julia Black, MIT Technology Review | 10.16.2025
Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of...
By Jared Whitlock, Endpoints News | 10.09.2025
When Nirnay Murthy learned about a treatment for his toddler son’s rare condition, relief quickly gave way to disappointment.
A one-time gene therapy called Zolgensma from the Swiss drugmaker Novartis can halt spinal muscular atrophy, a deadly condition that causes...
By Meagan Parrish, PharmaVoice | 10.10.2025
When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off...